Besides, MCT1 and MCT4 seem to be a target of Vorinostat, an HDAC inhibitor, resulting in a 30% reduction of intracellular lactate; affecting the metabolism of glioblastoma cells reflexed by a 40% decrease in the hyperpolarize hyperpolarized [1-13C] lactate measure by magnetic resonance spectroscopic imaging (MRSI), which in turn decreases the cell viability and tumor progression [230]. Here, SLC16A1 is linked to neoplasm.